This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BOLD Audentes Therapeutics (BOLD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Audentes Therapeutics Stock (NASDAQ:BOLD) 30 days 90 days 365 days Advanced Chart Get Audentes Therapeutics alerts:Sign Up Key Stats Today's Range$2.36▼$2.5850-Day Range$59.97▼$59.9752-Week Range$1.06▼$12.26Volume96,520 shsAverage Volume82,735 shsMarket Capitalization$34.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewAudentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.Read More… Audentes Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks5th Percentile Overall ScoreBOLD MarketRank™: Audentes Therapeutics scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Audentes Therapeutics.Read more about Audentes Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Audentes Therapeutics are expected to grow in the coming year, from ($3.85) to ($3.35) per share. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.26% of the float of Audentes Therapeutics has been sold short.Short Interest Ratio / Days to CoverAudentes Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Audentes Therapeutics has recently decreased by 30.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAudentes Therapeutics does not currently pay a dividend.Dividend GrowthAudentes Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.26% of the float of Audentes Therapeutics has been sold short.Short Interest Ratio / Days to CoverAudentes Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Audentes Therapeutics has recently decreased by 30.89%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Audentes Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Audentes Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Audentes Therapeutics is held by insiders.Read more about Audentes Therapeutics' insider trading history. Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Audentes Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BOLD Stock News HeadlinesBoundless Bio Announces Portfolio Prioritization and Runway ExtensionMay 23 at 4:01 PM | globenewswire.comBoundless Bio Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | globenewswire.comMemorial Day Sale! 82% Off Disruptors and Dominators!Nvidia's robot breakthrough, unveiled by CEO Jensen Huang at CES, could spark a $24T revolution. He said the "ChatGPT moment" for robotics is near. I believe the lives of 65M Americans could be impacted – this year. And one $7 stock could be the biggest winner.May 24, 2025 | Weiss Ratings (Ad)Boundless Bio to Participate in the Needham Virtual Healthcare ConferenceApril 3, 2025 | globenewswire.comBoundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsMarch 27, 2025 | globenewswire.comBoundless Bio to Participate in the Leerink Global Healthcare ConferenceFebruary 26, 2025 | globenewswire.comBoundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical OfficerFebruary 3, 2025 | globenewswire.comGuggenheim Downgrades Boundless Bio (BOLD)December 14, 2024 | msn.comSee More Headlines BOLD Stock Analysis - Frequently Asked Questions How were Audentes Therapeutics' earnings last quarter? Audentes Therapeutics Inc (NASDAQ:BOLD) posted its earnings results on Friday, May, 9th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by $0.03. When did Audentes Therapeutics IPO? Audentes Therapeutics (BOLD) raised $100 million in an initial public offering (IPO) on Thursday, March 28th 2024. The company issued 6,250,000 shares at a price of $16.00 per share. Who are Audentes Therapeutics' major shareholders? Audentes Therapeutics' top institutional investors include Nuveen LLC (17.75%). Insiders that own company stock include Ra Capital Management, LP and Kristina Burow. View institutional ownership trends. What other stocks do shareholders of Audentes Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Audentes Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings5/09/2025Today5/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BOLD CIK1628738 Webwww.audentestx.com Phone415-818-1001FaxN/AEmployees207Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-321.10% Return on Assets-40.02% Debt Debt-to-Equity RatioN/A Current Ratio17.03 Quick Ratio17.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares22,300,000Free Float21,118,000Market Cap$34.92 million OptionableNo Data BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:BOLD) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Hidden Energy Source Backed by Billionaires Why Billionaires Have Set Their Sights on the Utah Desert Something strange is happening near the Wah Wah ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.